[go: up one dir, main page]

WO2018155525A1 - Agent anti-inflammatoire - Google Patents

Agent anti-inflammatoire Download PDF

Info

Publication number
WO2018155525A1
WO2018155525A1 PCT/JP2018/006351 JP2018006351W WO2018155525A1 WO 2018155525 A1 WO2018155525 A1 WO 2018155525A1 JP 2018006351 W JP2018006351 W JP 2018006351W WO 2018155525 A1 WO2018155525 A1 WO 2018155525A1
Authority
WO
WIPO (PCT)
Prior art keywords
liver hydrolyzate
production
liver
inflammatory
hydrolyzate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2018/006351
Other languages
English (en)
Japanese (ja)
Inventor
耕太郎 山田
英知 櫻井
三千夫 駒井
仁 白川
圭佑 中村
プスポ エディ ギリウノ
一馬 植田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tohoku University NUC
Zeria Pharmaceutical Co Ltd
Original Assignee
Tohoku University NUC
Zeria Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tohoku University NUC, Zeria Pharmaceutical Co Ltd filed Critical Tohoku University NUC
Priority to JP2019501395A priority Critical patent/JP7216966B2/ja
Priority to KR1020197023135A priority patent/KR102608239B1/ko
Priority to SG11201907124YA priority patent/SG11201907124YA/en
Priority to CN201880007881.6A priority patent/CN110198723B/zh
Publication of WO2018155525A1 publication Critical patent/WO2018155525A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A23L33/28—Substances of animal origin, e.g. gelatin or collagen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/407—Liver; Hepatocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/20—Natural extracts
    • A23V2250/204—Animal extracts

Definitions

  • the present invention relates to a highly safe anti-inflammatory agent.
  • Non-patent Document 2 the antibody drug tricizumab is used (Non-patent Document 2). Furthermore, protein preparations and antibody drugs such as anakinra, rilonacept, and canakinumab have been developed as IL-1 inhibitors (Non-patent Document 3).
  • an object of the present invention is to provide a novel anti-inflammatory agent based on the inhibition of inflammatory cytokines which is highly safe and can be widely used.
  • the present inventor has examined the action on the production of inflammatory cytokines using various components.
  • liver hydrolysates that have been widely used for improvement of liver function, improvement of hangover in chronic liver disease, etc. Since it has a strong IL-1 production inhibitory action, it has been found that it is useful as an anti-inflammatory agent by suppressing the production of inflammatory cytokines.
  • the present invention provides the following [1] to [15].
  • An anti-inflammatory agent comprising liver hydrolyzate as an active ingredient.
  • An inflammatory cytokine production inhibitor comprising liver hydrolyzate as an active ingredient.
  • An IL-1 production inhibitor comprising liver hydrolyzate as an active ingredient.
  • a food composition for improving inflammation comprising liver hydrolyzate as an active ingredient.
  • a food composition for suppressing inflammatory cytokine production comprising liver hydrolyzate as an active ingredient.
  • a food composition for inhibiting IL-1 production comprising liver hydrolyzate as an active ingredient.
  • Use of liver hydrolyzate for the production of an anti-inflammatory agent Use of a liver hydrolyzate for producing an inflammatory cytokine production inhibitor.
  • liver hydrolyzate for producing an IL-1 production inhibitor.
  • a liver hydrolyzate for treating inflammatory diseases comprising administering an effective amount of a liver hydrolyzate.
  • a liver hydrolyzate for suppressing IL-1 production comprising administering an effective amount of a liver hydrolyzate.
  • a method for suppressing the production of inflammatory cytokines comprising administering an effective amount of liver hydrolyzate.
  • a method for inhibiting IL-1 production comprising administering an effective amount of a hydrolyzate of liver.
  • liver hydrolyzate has a strong inhibitory effect on IL-1 production, and therefore suppresses the production of inflammatory cytokines and is useful as an anti-inflammatory agent.
  • liver hydrolyzate can be administered orally, has few side effects, and is excellent in safety and usability, so it can also be used as a food composition.
  • liver hydrolyzate also called liver hydrolyzate, liver extract, liver decomposed extract, or liver hydrolyzate
  • liver hydrolyzate is obtained by hydrolyzing the liver with digestive enzymes etc., and is used as a liver function improving drug Is.
  • the liver which is a raw material, fresh livers such as cows, pigs, bonito and whales are used.
  • the obtained hydrolyzate is preferably used after being concentrated.
  • liver hydrolyzate defined as the pharmaceutical product is used.
  • Liver hydrolyzate contains various amino acids, nucleotides, vitamins, minerals, etc., mainly composed of low molecular weight peptides. More specifically, amino acids 19 to 78% by mass, peptides and proteins 17 to 73% by mass, sugars 1.8 to 11% by mass, lipids 0.005 to 0.04% by mass, and nucleic acids 0.7 to 2.5% by mass. %, Inorganic substances 1.6 to 5.4% by mass, vitamins 0.03 to 0.2% by mass, and glutathione 0.8% by mass or less are preferable.
  • the amino acid composition is Ala 17 to 68 mg / g, Arg 0.6 to 4.4 mg / g, Asp 9 to 48 mg / g, Cystein 5 mg / g or less, Glu 18 to 63 mg / g, Gly 10-39 mg / g, His 3-17 mg / g, Ile 14-56 mg / g, Leu 26-98 mg / g, Lys 15-65 mg / g, Met 0.3-20 mg / g, Phe 13-46 mg / g, Pro 10-48 mg / g, Ser 12-49 mg / g, Thr 12-45 mg / g, Trp 3-13 mg / g, Tyr 1.6-41 mg / g, Val 18-71 mg / g are preferred.
  • a low molecular weight fraction of liver hydrolyzate can also be used.
  • a fraction having a molecular weight of 3000 or less for example, a fraction obtained by collecting a fraction having a molecular weight of 3000 or less from the liver hydrolyzate using an ultrafiltration membrane or the like can be used.
  • liver hydrolyzate and low molecular weight fraction thereof have an action of strongly suppressing the production of IL-1 ⁇ , which is a kind of inflammatory cytokine, and an action of suppressing the expression of IL-1 ⁇ mRNA. . Therefore, the liver hydrolyzate suppresses the production of inflammatory cytokines typified by IL-1, and is useful as a therapeutic agent for inflammatory diseases involving inflammatory cytokines and a food and drink composition for improving inflammation.
  • diseases involving inflammatory cytokines include rheumatoid arthritis, osteoarthritis, inflammatory bowel disease, sepsis, acute and chronic myelogenous leukemia, osteoporosis, lifestyle-related diseases and the like.
  • the anti-inflammatory agent of the present invention can be administered by oral administration, transdermal administration, enteral administration, intravenous administration, etc., and oral administration is more preferred.
  • oral administration examples include liquids, tablets, powders, fine granules, granules, capsules and the like, but liquids and tablets are preferable, and liquids are more preferable.
  • preparations for oral administration include excipients such as lactose, mannitol, corn starch and crystalline cellulose, cellulose derivatives, binders such as gum arabic and gelatin, disintegrants such as carboxymethylcellulose calcium, talc, magnesium stearate And the like, solubilizers such as nonionic surfactants, flavoring agents, sweeteners, stabilizers, pH adjusters, water, ethanol, propylene glycol, glycerin and the like can be used. Further, a coating agent such as hydroxymethylcellulose phthalate, hydroxypropylmethylcellulose acetate succinate, cellulose acetate phthalate, and methacrylate copolymer may be used.
  • excipients such as lactose, mannitol, corn starch and crystalline cellulose, cellulose derivatives, binders such as gum arabic and gelatin, disintegrants such as carboxymethylcellulose calcium, talc, magnesium stearate And the like, solubilizers such as non
  • active ingredients can also be mix
  • Other active ingredients vitamins B 1 class; thiamine, thiamine mononitrate, thiamine hydrochloride, fursultiamine, bisbentiamine, Benhochiamin, thiamine disulfide, dicethiamine, thiamine propyl disulfide, and derivatives thereof, vitamin B 2 compounds; riboflavin and derivatives and their salts, vitamin B 3 compound; niacin, nicotinic acid, nicotinamide and derivatives and salts thereof, vitamin B 5 like; panthenol, pantothenic acid and derivatives and salts thereof, vitamin B 6 such; pyridoxine and derivatives and their salts, vitamin B 12 compound; cyanocobalamin and derivatives and salts thereof, other vitamins vitamin a, vitamin C, vitamin E, vitamin K, vitamin P, dichloroacetate diisopropylamine, taurine, chondro Itine sulfate,
  • the anti-inflammatory agent of the present invention is highly safe and can be administered orally, in addition to pharmaceuticals, quasi-drugs, health functional foods, sports drinks, rehabilitation drinks, functional foods such as pet foods, etc. It can also be used as a food composition.
  • liver hydrolyzate in the anti-inflammatory agent of the present invention varies depending on the administration form, but is usually preferably 0.001 to 10% by mass, more preferably 0.001 to 5% by mass as a dry weight. Further, the daily dosage of liver hydrolyzate in the anti-inflammatory agent of the present invention is preferably 100 mg to 1076 mg, more preferably 383 mg to 623 mg, and further preferably 351 mg to 680 mg as a dry weight.
  • Test example 1 The number of RAW264.7 cells was adjusted to 1.5 ⁇ 10 6 cells / dish, seeded, and cultured overnight. Both the pre-fractionation sample or the filtrate fraction were diluted 20-fold with EMEM medium (final concentration about 0.6 mg / mL). As a control, PBS was diluted 20-fold with EMEM medium instead of the sample. Each sample (control, pre-fractionation, filtrate fraction) diluted with a medium was added to each dish group. After 24 hours of culture, lipopolysaccharide (LPS) was added to a final concentration of 1.0 ⁇ g / mL. The mixture was allowed to stand for 3 hours, RNA was collected, and cDNA was synthesized by reverse transcription. Next, EEF1A1 and IL-1 ⁇ were measured by RT-RCR.
  • LPS lipopolysaccharide
  • liver hydrolyzate has an anti-inflammatory effect, and a physiologically active substance exhibiting an anti-inflammatory effect is present in a low molecular fraction having a molecular weight of 3000 or less in the liver hydrolyzate.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Le but de la présente invention est de proposer un nouvel agent anti-inflammatoire. L'agent anti-inflammatoire selon l'invention comprend un hydrolysat de foie comme principe actif.
PCT/JP2018/006351 2017-02-23 2018-02-22 Agent anti-inflammatoire Ceased WO2018155525A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2019501395A JP7216966B2 (ja) 2017-02-23 2018-02-22 抗炎症剤
KR1020197023135A KR102608239B1 (ko) 2017-02-23 2018-02-22 항염증제
SG11201907124YA SG11201907124YA (en) 2017-02-23 2018-02-22 Anti-inflammatory agent
CN201880007881.6A CN110198723B (zh) 2017-02-23 2018-02-22 抗炎药

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017-032541 2017-02-23
JP2017032541 2017-02-23

Publications (1)

Publication Number Publication Date
WO2018155525A1 true WO2018155525A1 (fr) 2018-08-30

Family

ID=63253284

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2018/006351 Ceased WO2018155525A1 (fr) 2017-02-23 2018-02-22 Agent anti-inflammatoire

Country Status (6)

Country Link
JP (1) JP7216966B2 (fr)
KR (1) KR102608239B1 (fr)
CN (1) CN110198723B (fr)
SG (2) SG10202108899XA (fr)
TW (1) TWI794210B (fr)
WO (1) WO2018155525A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019208701A1 (fr) * 2018-04-26 2019-10-31 ゼリア新薬工業株式会社 Composition pharmaceutique contenant un dipeptide
JP2023024673A (ja) * 2019-01-21 2023-02-16 和三郎 佐藤 神経機能再生促進剤

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0578252A (ja) * 1991-04-26 1993-03-30 Sansho Seiyaku Co Ltd 安定なｓｏｄ活性を有する胎盤または肝臓抽出液およびそれを含有する外用剤組成物
JP2002080388A (ja) * 2000-09-04 2002-03-19 Takeda Food Products Ltd 肝機能賦活剤
WO2015046184A1 (fr) * 2013-09-25 2015-04-02 ゼリア新薬工業株式会社 Agent améliorant la fonction hépatique et/ou agent améliorant la fonction pancréatique

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1254954A4 (fr) * 2000-02-08 2004-06-16 Ssp Co Ltd Methode de detection d'un ligand ou d'un compose a faible poids moleculaire du type ligand
JPWO2002074299A1 (ja) * 2000-12-27 2004-07-08 味の素株式会社 ＴＮＦα産生抑制剤
US20120225053A1 (en) * 2005-05-24 2012-09-06 Slavik Dushenkov Compositions and methods for the prevention and treatment of conditions associated with inflamation
BRPI0807269A2 (pt) * 2007-02-27 2014-04-29 Genentech Inc "anticorpo antagonista isolado, molécula de ácido nucléico isolada, vetor, célula hospedeira, composição, método de tratamento, método para tratamento, método para reduzir a severidade da asma, método para produzir um anticorpo, hibridoma, uso do anitocrpo, método para detectar ox40, kits e aparelhos médicos"
CN101356980B (zh) * 2008-09-04 2011-12-28 中国海洋大学 一种鱼肝脏水解物的制备方法及应用
JP5177901B2 (ja) * 2009-12-02 2013-04-10 株式会社明治 栄養組成物
CN102961404B (zh) * 2012-12-12 2014-05-14 青岛亚博生物科技有限公司 一种从动物器官提取的组合物的衍生物
CN103689626A (zh) * 2013-12-30 2014-04-02 徐州绿之野生物食品有限公司 一种营养食品及其加工方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0578252A (ja) * 1991-04-26 1993-03-30 Sansho Seiyaku Co Ltd 安定なｓｏｄ活性を有する胎盤または肝臓抽出液およびそれを含有する外用剤組成物
JP2002080388A (ja) * 2000-09-04 2002-03-19 Takeda Food Products Ltd 肝機能賦活剤
WO2015046184A1 (fr) * 2013-09-25 2015-04-02 ゼリア新薬工業株式会社 Agent améliorant la fonction hépatique et/ou agent améliorant la fonction pancréatique

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
TSUTSUI, SUEHARU ET AL.: "Therapeutic effect of liver hydrolyzate (Leviden) for chronic hepatic diseases", JOURNAL OF NEW REMEDIES & CLINICS, vol. 44, no. 9, 1995, pages 1570 - 1580 *
YANG, K. T. ET AL.: "Effects of chicken-liver hydrolysates on lipid metabolism in a high-fat diet", FOOD CHEM., vol. 160, 2014, pages 148 - 156, XP028660357 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019208701A1 (fr) * 2018-04-26 2019-10-31 ゼリア新薬工業株式会社 Composition pharmaceutique contenant un dipeptide
JPWO2019208701A1 (ja) * 2018-04-26 2021-05-13 ゼリア新薬工業株式会社 ジペプチドを含有する医薬組成物
JP2023024673A (ja) * 2019-01-21 2023-02-16 和三郎 佐藤 神経機能再生促進剤
JP7589217B2 (ja) 2019-01-21 2024-11-25 和三郎 佐藤 神経機能再生促進剤

Also Published As

Publication number Publication date
KR20190119039A (ko) 2019-10-21
TWI794210B (zh) 2023-03-01
SG11201907124YA (en) 2019-09-27
CN110198723A (zh) 2019-09-03
KR102608239B1 (ko) 2023-11-30
JP7216966B2 (ja) 2023-02-02
CN110198723B (zh) 2024-03-05
JPWO2018155525A1 (ja) 2019-12-12
SG10202108899XA (en) 2021-09-29
TW201834670A (zh) 2018-10-01

Similar Documents

Publication Publication Date Title
CN104220084A (zh) 包含土茯苓提取物作为有效成分的肥胖、高脂血症或脂肪肝的预防或治疗用药剂学组合物
JP6293099B2 (ja) ジンセノサイドｆ２の肝疾患予防又は治療用途
WO2004078191A1 (fr) Composition destinee a traiter l'hepatite c
JP7216966B2 (ja) 抗炎症剤
CN108697723B (zh) 鬼针草对增加肌肉和减少脂肪的有益效果
JP4824152B2 (ja) 血流改善剤
KR102285327B1 (ko) 간장 기능 및/또는 췌장 기능의 개선제
KR102608920B1 (ko) 시크니스 비헤이비어 증상 개선제
KR102270850B1 (ko) 관절염 예방 또는 치료용 약학 조성물
KR101882492B1 (ko) 페룰릭산 및 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 식욕억제용 약학적 조성물
JPWO2018079695A1 (ja) 認知機能低下抑制剤
KR20140137557A (ko) 애엽과 전호의 추출 혼합물을 주성분으로 하는 염증성 질환 예방 및 치료용 치료용 천연물 조성물
JP5144000B2 (ja) 形質転換増殖因子β抑制用組成物
CN105451748B (zh) Amp活化蛋白激酶活化剂
JP6708376B2 (ja) ＩＦＮ−γ及び／又はＩＬ−１７の産生抑制剤、並びにＴｈ１細胞及び／又はＴｈ１７細胞の分化抑制剤
TWI822770B (zh) 含有二肽之醫藥組合物
KR101588229B1 (ko) 마치현 추출물을 유효성분으로 함유하는 급성 췌장염의 예방, 개선 또는 치료를 위한 조성물
TW202402190A (zh) 包含源自乳清蛋白的肽的生長促進用組合物
KR20230122478A (ko) 8-쇼가올을 포함하는 약학적 조성물
JP5462323B2 (ja) 神経ペプチドｗ発現増強剤及び摂食抑制剤
JP2007176823A (ja) 関節リウマチ予防用又は治療用組成物、並びにそれらの組成物を含有する関節リウマチ予防又は治療剤及び飲食物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18756799

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 20197023135

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2019501395

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18756799

Country of ref document: EP

Kind code of ref document: A1